Compare ALAR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | CMMB |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 13.8M |
| IPO Year | 2018 | 2023 |
| Metric | ALAR | CMMB |
|---|---|---|
| Price | $1.67 | $2.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 108.3K | 64.0K |
| Earning Date | 05-28-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $24.51 | N/A |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | ★ $44.31 | $54.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $1.35 |
| 52 Week High | $18.00 | $3.78 |
| Indicator | ALAR | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 24.64 | N/A |
| Support Level | $1.62 | N/A |
| Resistance Level | $2.10 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 9.09 | 0.00 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.